Peroral Amphotericin B Polymer Nanoparticles Lead to Comparable or Superior In Vivo Antifungal Activity to That of Intravenous Ambisome® or Fungizone™
Year: 2011
Type: article
Abstract: BACKGROUND: Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis remains unacceptably high (70-90%) in immunocompromised patients. Amphotericin B (AMB), a polyene antibiotic with broad spectrum antifungal activity appears to be a choice of treatment but is available only as an intravenous formulation; development of an oral formulation would be beneficial as well as economical. METHODOLOGY: Poly(lactide-co-glycolode) (PLGA) nanoparticles encapsulating AMB (AMB-NPs) were developed for oral administration. The AMB-NPs were 113 ± 20 nm in size with ~70% entrapment efficiency at 30% AMB w/w of polymer. The in vivo therapeutic efficacy of oral AMB-NPs was evaluated in neutropenic murine models of disseminated and invasive pulmonary aspergillosis. AMB-NPs exhibited comparable or superior efficacy to that of Ambisome® or Fungizone™ administered parenterally indicating potential of NPs as carrier for oral delivery. CONCLUSIONS: The present investigation describes an efficient way of producing AMB-NPs with higher AMB pay-load and entrapment efficiency employing DMSO as solvent and ethanol as non-solvent. The developed oral formulation was highly efficacious in murine models of disseminated aspergillosis as well as an invasive pulmonary aspergillosis, which is refractory to treatment with IP Fungizone™ and responds only modestly to AmBisome®.
Source: PLoS ONE
Institutions: University of Strathclyde, University of Manchester
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: amphotericin B, polymeric nanoparticles, PLGA nanoparticles, oral drug delivery, invasive pulmonary aspergillosis, disseminated aspergillosis, antifungal activity, liposomal amphotericin B, Fungizone, encapsulation efficiency, neutropenic mice, immunocompromised patients, nanoparticle formulation
Open Access status: gold
Estimated APC paid: $2,382
OpenAlex ID: W2164812014
